Search
Itraconazole
go.drugbank.com/drugs/DB01167ApprovedInvestigationalFirst synthesized in the early 1980s, itraconazole is a broad-spectrum triazole antifungal agent used to treat a variety of infections. It is a 1:1:1:1 racemic mixture of four diastereomers, made up of two enantiomeric pairs, each posses...
Products: ITRACONAZOLO DOC GENERICI, ITRACONAZOLO MYLAN GENERICSOnion
go.drugbank.com/drugs/DB10548ApprovedOnion allergenic extract is used in allergenic testing.
Mixtures: BARICUS 50 IU/%1/%10 JEL , 50 G, NOSKAR 100 MG/50 IU/10 MG / G, JEL 120 GQuinidine
go.drugbank.com/drugs/DB00908ApprovedThis alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species.
Demecarium
go.drugbank.com/drugs/DB00944ApprovedDemecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase.
TAK-428
go.drugbank.com/drugs/DB05499ExperimentalIt is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Hemoglobin
go.drugbank.com/drugs/DB04945ApprovedInvestigationalWithdrawnThe respiratory protein of the red blood cells. It consists primarily of globin and heme.
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalIt was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.
Sulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalSulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Dapoxetine
go.drugbank.com/drugs/DB04884InvestigationalIn October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions. … Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004.
DAR-0100A
go.drugbank.com/drugs/DB16139InvestigationalDAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Categories: Dopamine D1 Receptor Agonists